Haitron "Acquires $13.8 Million Worth of Shares in U.S. Subsidiary"

Haitron announced on the 5th that it will acquire 3,333,333 shares of Exicure, a U.S. nucleic acid therapeutic drug development company, for approximately 13.8 billion KRW.

After acquiring the shares, the ownership stake will be 60.5%. The scheduled date for the stock acquisition is the 14th.

Haitron stated that the purpose of this stock acquisition is a "paid-in capital increase for business expansion."

This content was produced with the assistance of AI translation services.